Canine Lymphoma: Overcoming Treatment Hurdles & Maximizing Patient Options with Dr. Ettinger

We all know it too well: that sinking feeling when we see the golden retriever scheduled for “check lumps on neck.” But we can do more than ever to treat canine lymphoma with a novel drug. In this episode of Clinician’s Brief Partner Podcast, host Dr. Beth Molleson sits down with Dr. Sue “Cancer Vet” Ettinger to discuss canine lymphoma and a novel treatment option to overcome hurdles regarding access to care, including affordability and convenience. Dr. Ettinger shares her “investigate before you tell” approach to conversations with pet owners, why you shouldn’t start a lymphoma patient on prednisone if they are being referred to an oncologist, and where this novel drug can fit in for a general practitioner.

Sponsored by Dechra

Resource:

• https://go.dechra-us.com/laverdia

Contact us:

• Podcast@briefmedia.com

Where to find us:

• Cliniciansbrief.com/podcasts
• Facebook.com/clinciansbrief
• Twitter: @cliniciansbrief
• Instagram: @clinicians.brief

The Team:

• Beth Molleson, DVM - Host
• Sarah Pate - Producer & Project Manager, Brief Studio
• Randall Stupka - Podcast Production & Sound Editing

Important Safety Information

For use in dogs only. Laverdia™-CA1 (verdinexor tablets) is conditionally approved for the treatment of lymphoma in dogs. NOT FOR USE IN HUMANS. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. CHILDREN SHOULD NOT COME INTO CONTACT WITH LAVERDIA-CA1. Pregnant women, women who may become pregnant, nursing women and children should not handle or administer Laverdia-CA1 or come into contact with the feces, urine, saliva, or vomit of treated dogs for 3 days following treatment. Laverdia-CA1 can affect male fertility based on animal studies and studies in humans. Wear protective disposable chemotherapy resistant gloves when handling Laverdia-CA1 to avoid direct exposure to moistened, broken or crushed tablets or biological waste from the treated dog (feces, urine, saliva, or vomit). Do not use in dogs that are pregnant, lactating or intended for breeding. Laverdia-CA1 is a possible teratogen and can affect female and male fertility. Dogs should be frequently monitored for hematologic and serum chemistry abnormalities. The most commonly reported adverse reactions in dogs include anorexia, weight loss, vomiting, diarrhea, lethargy, polyuria, polydipsia, elevated liver enzymes and thrombocytopenia. Please see package insert or visit dechra-us.com for full prescribing information.